|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.Japan |
First Approval Date27 May 1983 |
|
MechanismmAChRs antagonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.Japan |
First Approval Date20 Jul 1968 |
A Randomized, Double-Blind, Placebo-Controlled Dose Finding Study of 0.05%, 0.025%, 0.01% and 0.005% Atropine Eye Drops to inhibit myopia progression in children in a European population
吸入用盐酸氨溴索溶液在中国健康人群人体药代动力学研究
[Translation] Study on the pharmacokinetics of inhaled ambroxol hydrochloride solution in healthy Chinese subjects
主要目的:评价健康的中国成年男性和女性受试者雾化吸入吸入用盐酸氨溴索溶液后体内的药代动力学特征。次要目的:评价空腹状态下,雾化吸入吸入用盐酸氨溴索溶液安全性。
[Translation] The primary objective is to evaluate the pharmacokinetic characteristics of ambroxol hydrochloride solution after nebulized inhalation in healthy Chinese adult male and female subjects. The secondary objective is to evaluate the safety of ambroxol hydrochloride solution after nebulized inhalation in the fasting state.
吸入用盐酸氨溴索溶液在中国健康人群人体药代动力学研究预试验
[Translation] A pilot study on the pharmacokinetics of inhaled ambroxol hydrochloride solution in healthy Chinese subjects
主要目的:评价健康的中国成年男性和女性受试者雾化吸入吸入用盐酸氨溴索溶液后主要药代动力学参数。次要目的:验证生物样本分析方法的合理性;为采血时间设计提供参考依据;评价空腹状态下,雾化吸入吸入用盐酸氨溴索溶液安全性。
[Translation] The primary objective is to evaluate the main pharmacokinetic parameters of ambroxol hydrochloride solution after nebulized inhalation in healthy Chinese adult male and female subjects. The secondary objectives are to verify the rationality of the biological sample analysis method; to provide a reference for the design of blood sampling time; to evaluate the safety of ambroxol hydrochloride solution after nebulized inhalation in the fasting state.
100 Clinical Results associated with Pharma Stulln GmbH
0 Patents (Medical) associated with Pharma Stulln GmbH
100 Deals associated with Pharma Stulln GmbH
100 Translational Medicine associated with Pharma Stulln GmbH